These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8049305)

  • 21. Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide purged marrows for children with acute non-lymphoblastic leukemia in second remission.
    Lenarsky C; Weinberg K; Petersen J; Nolta J; Brooks J; Annett G; Kohn D; Parkman R
    Bone Marrow Transplant; 1990 Dec; 6(6):425-9. PubMed ID: 2097012
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Allogeneic and autologous bone marrow transplantation after consolidation therapy in high-risk acute myeloid leukemia in children. Towards a risk-oriented therapy.
    Ortega JJ; Díaz de Heredia C; Olivé T; Bastida P; Llort A; Armadans L; Torrabadella M; Massuet L
    Haematologica; 2003 Mar; 88(3):290-9. PubMed ID: 12651268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prolonged remission of accelerated phase Philadelphia chromosome negative chronic myeloid leukemia following autologous recovery of normal hematopoietic elements after busulfan/cyclophosphamide and allogeneic marrow transplantation.
    Kapoor N; Keever CA; Hsu SH; Copelan EA; Tutschka PJ
    Bone Marrow Transplant; 1992 Feb; 9(2):143-5. PubMed ID: 1349249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Understanding the mechanism of cure of acute myeloid leukemia by allogeneic bone marrow transplantation: toward the application of interleukin-2 in autologous bone marrow transplantation.
    Prentice HG; MacDonald ID; Hamon MD
    J Hematother; 1994; 3(1):47-50. PubMed ID: 7922008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia.
    Baker KS; Bostrom B; DeFor T; Ramsay NK; Woods WG; Blazar BR
    Bone Marrow Transplant; 2000 Sep; 26(6):607-14. PubMed ID: 11041565
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preliminary results of high-dose busulfan and cyclophosphamide with syngeneic or autologous bone marrow rescue.
    Lu C; Braine HG; Kaizer H; Saral R; Tutschka PJ; Santos GW
    Cancer Treat Rep; 1984 May; 68(5):711-7. PubMed ID: 6373004
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts.
    Heslop HE; Brenner MK; Rooney C; Krance RA; Roberts WM; Rochester R; Smith CA; Turner V; Sixbey J; Moen R
    Hum Gene Ther; 1994 Mar; 5(3):381-97. PubMed ID: 8018749
    [No Abstract]   [Full Text] [Related]  

  • 28. Retrospective evaluation of autologous bone marrow transplantation vs allogeneic bone marrow transplantation from an HLA identical related donor in acute myelocytic leukemia. A study of the European Cooperative Group for Blood and Marrow Transplantation (EBMT).
    Gorin NC; Labopin M; Fouillard L; Meloni G; Frassoni F; Iriondo A; Brunet Mauri S; Goldstone AH; Harousseau JL; Reiffers J; Esperou-Bourdeau H; Gluckman E
    Bone Marrow Transplant; 1996 Jul; 18(1):111-7. PubMed ID: 8832003
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Idarubicin to intensify the conditioning regimens of autologous bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
    Jerjis S; Roovers E; Muus P; Schaap N; de Witte T
    Bone Marrow Transplant; 1998 Jul; 22(1):13-9. PubMed ID: 9678790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The sensitivity of leukemic bone marrow to simvastatin is lost at remission: a potential purging agent for autologous bone marrow transplantation.
    Newman A; Clutterbuck RD; DeLord C; Powles RL; Catovsky D; Millar JL
    J Investig Med; 1995 Jun; 43(3):269-74. PubMed ID: 7614073
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autologous BMT in high risk patients with CALLA-positive ALL: possible efficacy of ex vivo marrow leukemia cell purging with monoclonal antibodies and complement.
    Morishima Y; Miyamura K; Kojima S; Ueda R; Morishita Y; Sao H; Tanimoto M; Ohno R; Sobue R; Hirano M
    Bone Marrow Transplant; 1993 Apr; 11(4):255-9. PubMed ID: 7683550
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II pilot study of high-dose busulfan and CY followed by autologous BM or peripheral blood stem cell transplantation in patients with advanced chemosensitive breast cancer.
    Klumpp TR; Mangan KF; Glenn LD; Macdonald JS
    Bone Marrow Transplant; 1993 Apr; 11(4):337-9. PubMed ID: 8097937
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia?
    Vellenga E; van Putten WL; Boogaerts MA; Daenen SM; Verhoef GE; Hagenbeek A; Jonkhoff AR; Huijgens PC; Verdonck LF; van der Lelie J; Schouten HC; Gmür J; Wijermans P; Gratwohl A; Hess U; Fey MF; Löwenberg B
    Bone Marrow Transplant; 1999 Jun; 23(12):1279-82. PubMed ID: 10414916
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autologous bone marrow transplantation for haematological malignancies--experiences of the centre of Zagreb.
    Nemet D; Labar B; Bogdanic V; Skodlar J; Petrovecki M; Mrsic M; Maravic N; Sneller V; Radman I; Kovacevic-Metelko J
    Wien Med Wochenschr; 1995; 145(2-3):61-4. PubMed ID: 7762256
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autologous bone marrow transplant for children with AML in first complete remission: use of marker genes to investigate the biology of marrow reconstitution and the mechanism of relapse.
    Hum Gene Ther; 1991; 2(2):137-59. PubMed ID: 1911934
    [No Abstract]   [Full Text] [Related]  

  • 36. Genetically marking human cells--results of the first clinical gene transfer studies.
    Cai Q; Rubin JT; Lotze MT
    Cancer Gene Ther; 1995 Jun; 2(2):125-36. PubMed ID: 7621260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Busulfan plus etoposide as a preparative regimen for autologous bone marrow transplantation for acute myelogenous leukemia: an update.
    Linker CA; Damon LE; Ries CA; Rugo HS; Wolf JL
    Semin Oncol; 1993 Aug; 20(4 Suppl 4):40-8; quiz 49. PubMed ID: 8342075
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I study of cytokine-gene modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma.
    Hum Gene Ther; 1992 Dec; 3(6):665-76. PubMed ID: 1482707
    [No Abstract]   [Full Text] [Related]  

  • 39. A phase I trial of high-dose carboplatin and etoposide with autologous marrow support for treatment of relapse/refractory neuroblastoma without apparent bone marrow involvement: use of marker genes to investigate the biology of marrow reconstitution and the mechanism of relapse.
    Hum Gene Ther; 1991; 2(3):273-86. PubMed ID: 1661173
    [No Abstract]   [Full Text] [Related]  

  • 40. Use of retroviral markers to identify efficacy of purging and origin of relapse following autologous bone marrow and peripheral blood cell transplantation in indolent B cell neoplasms (follicular non-Hodgkin's lymphoma or chronic lymphocytic leukemia (CLL) patients).
    Hum Gene Ther; 1993 Dec; 4(6):821-34. PubMed ID: 8186294
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.